Pathologic Assessment of Response to Chemotherapy in Colorectal Cancer Liver Metastases after Hepatic Resection: Which Method to Use?

被引:13
作者
Dede, K. [1 ]
Salamon, F. [2 ]
Landherr, L. [3 ]
Jakab, F. [1 ]
Bursics, A. [1 ]
机构
[1] Uzsoki Teaching Hosp, Dept Surg Oncol Surg, H-1145 Budapest, Hungary
[2] Uzsoki Teaching Hosp, Dept Pathol, H-1145 Budapest, Hungary
[3] Uzsoki Teaching Hosp, Dept Oncol, H-1145 Budapest, Hungary
关键词
colorectal cancer liver metastases; Preoperative chemotherapy; Pathologic response; PREOPERATIVE CHEMOTHERAPY; BEVACIZUMAB; SURGERY; TUMOR; OXALIPLATIN; SURVIVAL; NECROSIS;
D O I
10.1007/s12253-014-9803-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with metastatic colorectal cancer receive chemotherapy prior liver resection more and more frequently. Histopathologic assessment methods of the resected specimen could evaluate the response to chemotherapy. In this study it is analyzed if these histopathologic changes are specific to preoperative chemotherapy and if these methods have correlation with survival. Sixty three patients with available pathology slides, resected for colorectal cancer liver metastases were enrolled in this study. 46 patients (73 %) received neoadjuvant chemotherapy. Five pathological evaluation methods were compared according to the literature: [1] residual tumor cell ratio, [2] tumor regression grade (TRG) scoring system, [3] modified tumor regression grade (mTRG) scoring system with the type of necrosis, [4] pattern of tumor regression and [5] the tumor thickness at the tumor-normal interface (TNI). Analyzing the pathological methods between the chemotherapy (CTX) and the non-chemotherapy group (NC), we found that that four evaluation methods showed significant and one showed strong correlation with the use of chemotherapy. (Residual tumor cell ratio: p = 0.08; TRG: p < 0.01; mTRG: p = 0.03; pattern of tumor regression: p < 0.01; TNI: p = 0.02). In the chemotherapy group none of the analyzed pathological methods showed significant correlation with progression free survival (PFS) or with overall survival (OS). Residual tumor cell ratio, TRG and the pattern of tumor cells showed positive but not significant correlation with OS and PFS and a slight difference in the group of patients with TNI < 2 mm could be documented. Tumor regression grade (TRG) and tumor thickness at the tumor-normal interface (TNI) were the most useful methods for pathological response evaluation and these methods had some correlation with survival. According to these data, authors concluded, that a reproducible and well defined scoring system, based on different histopathological evaluation methods should be developed to predict more accurately the effect of neoadjuvant chemotherapy in CRCLM patients.
引用
收藏
页码:173 / 179
页数:7
相关论文
共 24 条
  • [1] Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
  • [2] Infarct-like Necrosis: A Distinct Form of Necrosis Seen in Colorectal Carcinoma Liver Metastases Treated With Perioperative Chemotherapy
    Chang, Hector H. Li
    Leeper, W. Robert
    Chan, Gabriel
    Quan, Douglas
    Driman, David Kevin
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (04) : 570 - 576
  • [3] Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver Metastases
    Chua, Terence C.
    Saxena, Akshat
    Liauw, Winston
    Kokandi, Adel
    Morris, David L.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (02) : 492 - 501
  • [4] Chun YS, JAMA, V2, P2338
  • [5] Dan G, 2008, J CLIN ONCOL, V25, P5344
  • [6] Bevacizumab Treatment Before Resection of Colorectal Liver Metastases: Safety, Recovery of Liver Function, Pathologic Assesment
    Dede, K.
    Mersich, T.
    Besznyak, I.
    Zarand, A.
    Salamon, F.
    Baranyai, Zs.
    Landherr, L.
    Jakab, F.
    Bursics, A.
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2013, 19 (03) : 501 - 508
  • [7] Dede Kristof, 2013, Magy Seb, V66, P325, DOI 10.1556/MaSeb.66.2013.6.4
  • [8] Assessment of Chemotherapy Response in Colorectal Liver Metastases in Patients Undergoing Hepatic Resection and the Correlation to Pathologic Residual Viable Tumor
    Egger, Michael E.
    Cannon, Robert M.
    Metzger, Tiffany L.
    Nowacki, Michael
    Kelly, Larry
    Tatum, Cliff
    Scoggins, Charles R.
    Callender, Glenda G.
    McMasters, Kelly M.
    Martin, Robert C. G., II
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2013, 216 (04) : 845 - 856
  • [9] Gomez Dorronsoro ML, CLIN TRANSL ONCOL
  • [10] Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
    Gruenberger, Brigit
    Tamandl, Dietmar
    Schueller, Johannes
    Scheithauer, Werner
    Zielinski, Christoph
    Herbst, Friedrich
    Gruenberger, Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1830 - 1835